Medibank shares soar to 52-week high on US tech partnership

2 min read | February 20, 2024 07:42 PM AEDT | By Team Kalkine Media

The Medibank Private Ltd (ASX: MPL) share price has surged by 2.5% to reach a 52-week high of $3.89 in afternoon trade on Tuesday. This significant increase contrasts with the ASX 200 index, which is currently down by 0.15%. ASX financial stocks, encompassing various banking, insurance, and other financial services companies, are closely monitored alongside Medibank Private Ltd's performance for insights into market trends and investor sentiment in the financial sector. 

Reasons Behind the Surge: 

Investors are responding positively to news of a new partnership announced by the company. Medibank's Amplar Health business has entered into a partnership with Amwell, a leading US-based healthcare technology company. This collaboration aims to support the delivery of prevention programs on a large scale in Australia. 

According to the announcement, this partnership will expedite the implementation of digital health solutions to assist more Australians who are at risk of chronic diseases. Robert Read, Group Lead of Amplar Health, highlighted the rising prevalence of preventable chronic diseases in Australia, which have significant economic costs and contribute to a high burden of disease. 

Read emphasized the importance of utilizing virtual solutions to address these health challenges effectively. He noted that virtual platforms can empower individuals to set health goals, adopt positive lifestyle changes, and sustain them over time. By offering accessible preventative programs, these technologies aim to alleviate pressure on hospitals caused by preventable diseases and improve health outcomes for patients. 

Outlook for Medibank: 

With the anticipation building for Medibank's half-year results set to be released on Thursday, shareholders are hopeful that the positive momentum from this partnership announcement will continue to drive the Medibank share price higher. 

As the company continues to focus on innovative solutions and partnerships to address healthcare challenges, investors remain optimistic about its future growth prospects. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.